Autopsy report · NCT05458102

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

“Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 8 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Gilead Sciences

Sponsor type

Industry

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Interventions

Vesatolimod; Cobicistat; Voriconazole; Rifabutin

Participants

18

Sites

5

Countries

United States

Trials that died the same way

• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
  “Due to sponsor decision, not for efficacy or safety reasons.” (68% match in meaning)
• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (67% match in meaning)
• Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome
  “Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients” (66% match in meaning)
• COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
  “The sponsor has changed the development plans which is not for safety reasons.” (66% match in meaning)
• Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.
  “The compound is no longer suitable for further clinical development due to a safety finding in a later phase program.” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.